Target intelligence / Profile preview

Alpha-L-fucosidase 1 (FUCA1)

Target
FUCA1
Molecular classification
Enzyme, Glycoside hydrolase, Lysosomal hydrolase, Carbohydrate-active enzyme (CAZy GH29 family)
01

Overview

Alpha-L-fucosidase 1 is a lysosomal glycoside hydrolase (EC 3.2.1.51) encoded by the FUCA1 gene. It hydrolyzes terminal L-fucose residues from glycans bound to glycoproteins and glycolipids, serving a crucial role in cellular glycan degradation. Genetic deficiency of this enzyme leads to fucosidosis, a lysosomal storage disorder characterized by progressive neurological decline, organomegaly, and characteristic skin and skeletal findings[2]. Structurally, alpha-L-fucosidase 1 belongs to the CAZy GH29 family and exhibits a barrel-fold architecture, with catalytic activity reliant on conserved nucleophile and acid/base residues[1][4]. Variant isoforms exist in microbes, but the human enzyme’s clinical significance stems primarily from its role in cellular metabolism and inherited disease, with ongoing research into biomarker and biotechnological applications.

Other names
FUCA1Alpha-L-fucosidase isoenzyme 1α-L-fucosidase 1EC 3.2.1.51
02

Mechanism of action

Inhibitors (if developed) would block L-fucose cleavage, causing increased glycan accumulation; enzyme replacement or gene therapy aims to restore function in deficient patients.

03

Biological functions

Breakdown of oligosaccharides, glycolipids, and glycoproteins in lysosomes by removing terminal L-fucose moietiesGlycan catabolismTransglycosylation (to a limited extent)
04

Disease associations

Lysosomal storage disorder (Fucosidosis)Neurological disease due to substrate accumulationPossible relevance in cancer (through altered glycosylation)Other metabolic glycan storage disorders
05

Safety considerations

Enzyme deficiency leads to accumulation of glycolipids and glycoproteins in lysosomes, causing multisystem dysfunction (notably neurological, hepatic, and cutaneous symptoms)Enzyme modulation could have broad effects on glycan metabolism
06

Interacting drugs

None currently approved that directly target FUCA1

2 more in the full profile.

07

Biomarkers

Deficiency of FUCA1 enzyme activity in blood or tissuesGlycan substrates (indirect biomarkers)

Beyond the preview

Go deeper on Alpha-L-fucosidase 1 (FUCA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-L-fucosidase 1 (FUCA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call